Antipsychotics Linked to Increased Deaths in Alzheimer’s Part 2
The traditional treatment of behavior problems in Alzheimer dementia is anti psychotics like Thioridazine, chlorpromazine, haloperidol, Trifluoperazine, Risperdal, Zyprexa, and Seroquel. These drugs are the top selling medications in almost every western country.
The medications are effective and can treat a range of personality changes, anxiety, paranoia and panic associated with dementia. However, the drugs also have potent side effects and can also induce severe irreversible motor movements.
Alzheimer’s disease has no cure and the few drugs available only work in the early stages. Globally the cost of dementia is close to $315 billion, the majority of which is spent by the western countries.
Now with the British study, some health professional suggest that anti psychotics should only be used as a last resort. Says Dr Neil Hunt, CEO of Britain’s Alzheimer's Society, "The scandalous over prescription of antipsychotic drugs leads to an estimated 1,800 deaths a year. It must end."
Earlier this year, a study published by British scientists revealed that anti psychotics prescribed to older AD patients increased the risk of premature death.
We value and respect the experiences of all of our HERWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.
Add a Comment2 Comments
Internal company documents from Eli Lilly & Co. show it urged doctors to prescribe the house drug, Zyprexa, to elderly patients suffering from dementia when fully aware that it had absolutely no beneficial effect against the disease.
Zyprexa was developed and intended for use as an antipsychotic (a drug for the treatment of diseases such as bipolar disorder and schizophrenia that works by blocking receptors in the brain's dopaminergic pathways).
At best, "antipsychotic medication is not generally regarded as a good treatment, just the best available."
In 1999, four years after Lilly sent study results to the U.S. Food and Drug Administration showing Zyprexa didn’t alleviate dementia symptoms in older patients, it began marketing the drug to those very people. . .Bloomberg
---
November 18, 2009 - 2:52amDaniel Haszard Zyprexa Whistle Blower http://www.zyprexa-victims.com
This Comment
thanks for comment. It is now being revealed that several drug companies hid negative or normal results and yet marketed the drug for use in humans..sb
November 25, 2009 - 5:04pm